Issue 26, 2018, Issue in Progress
From the journal:

RSC Advances

Thymoquinone protects against cardiac damage from doxorubicin-induced heart failure in Sprague-Dawley rats

Zuowei Pei, ORCID logo a   Jiahui Hu,ab   Qianru Bai,ab   Baiting Liu,c   Dong Cheng,a   Hainiang Liu,a   Rongmei Naa  and  Qin Yu*a  

* Corresponding authors

a Department of Cardiology, Affiliated Zhongshan Hospital of Dalian University, No. 6 Jiefang Street, Dalian, China
E-mail: yuqin@dlu.edu.cn
Fax: +86-0411-62893517
Tel: +86-0411-62893517

b Graduate School of Dalian Medical University, No. 9 Lvshun South Road, Dalian, China

c International Medical Department, Affiliated Zhongshan Hospital of Dalian University, No. 6 Jiefang Street, Dalian, China

Abstract

Heart failure is a complex end stage result of various cardiovascular diseases, and has a poor prognosis. The mechanisms for the development and progression of heart failure have always been an important topic in cardiovascular research, and previous studies have shown that thymoquinone (TQ) protects against cardiotoxicity and cardiac damage. The aim of this study was to investigate the possible protective effects of thymoquinone against cardiac damage in doxorubicin (DOX)-induced heart failure in Sprague-Dawley Rats (SDR). Forty-five male SDR were randomly divided into three groups and administered different treatment regimens for 8 weeks. Left ventricular fractional shortening (LVFS) and ejection fraction (LVEF) were higher in the DOX + TQ group than those in the DOX group. Significant pathophysiology changes (HE and Masson staining) were observed in rats of the DOX group compared to those of the DOX + TQ group. The addition of Thymoquinone inhibited DOX-induced cardiac fibrosis (TGF-β, Smad3, collagen I, collagen III, and α-SMA) and apoptosis (P53, bcl-2, caspase-3, caspase-9, and BAX) in SDR, indicating that thymoquinone may be a potential therapeutic target for cardiac damage caused by DOX-induced heart failure.

Graphical abstract: Thymoquinone protects against cardiac damage from doxorubicin-induced heart failure in Sprague-Dawley rats

About
Cited by
Related
Download options Please wait...

Article information

DOI
https://doi.org/10.1039/C8RA00975A
Article type
Paper
Submitted
31 Jan 2018
Accepted
26 Mar 2018
First published
18 Apr 2018
This article is Open Access
Creative Commons BY-NC license

RSC Adv., 2018,8, 14633-14639

Permissions

Request permissions

Thymoquinone protects against cardiac damage from doxorubicin-induced heart failure in Sprague-Dawley rats

Z. Pei, J. Hu, Q. Bai, B. Liu, D. Cheng, H. Liu, R. Na and Q. Yu, RSC Adv., 2018, 8, 14633 DOI: 10.1039/C8RA00975A

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. You can use material from this article in other publications, without requesting further permission from the RSC, provided that the correct acknowledgement is given and it is not used for commercial purposes.

To request permission to reproduce material from this article in a commercial publication, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party commercial publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements